In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $131.45 in the prior trading day, Intra-Cellular Therapies Inc (NASDAQ: ITCI) closed at $131.53, up 0.06%. In other words, the price has increased by $0.06 from its previous closing price. On the day, 1.23 million shares were traded. ITCI stock price reached its highest trading level at $131.57 during the session, while it also had its lowest trading level at $131.45.
Ratios:
Our goal is to gain a better understanding of ITCI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.23 and its Current Ratio is at 6.36. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on February 24, 2025, Downgraded its rating to Neutral and sets its target price to $132 from $140 previously.
On January 31, 2025, Canaccord Genuity Downgraded its rating to Hold which previously was Buy and also upped its target price recommendation from $119 to $132.
Piper Sandler Upgraded its Neutral to Overweight on September 06, 2024, whereas the target price for the stock was revised from $68 to $92.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 18 ’25 when ALEXANDRIA VENTURE INVESTMENTS bought 20,000 shares for $131.42 per share.
ALEXANDRIA VENTURE INVESTMENTS bought 11,750 shares of ITCI for $1,544,292 on Mar 17 ’25. On Dec 04 ’24, another insider, Mates Sharon, who serves as the Chairman and CEO of the company, sold 51,000 shares for $85.80 each. As a result, the insider received 4,375,659 and left with 1,070,329 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ITCI now has a Market Capitalization of 13985321984 and an Enterprise Value of 13001230336. For the stock, the TTM Price-to-Sale (P/S) ratio is 20.54 while its Price-to-Book (P/B) ratio in mrq is 12.17. Its current Enterprise Value per Revenue stands at 19.096 whereas that against EBITDA is -111.874.
Stock Price History:
The Beta on a monthly basis for ITCI is 0.46, which has changed by 0.9235157 over the last 52 weeks, in comparison to a change of 0.08275449 over the same period for the S&P500. Over the past 52 weeks, ITCI has reached a high of $131.48, while it has fallen to a 52-week low of $63.87. The 50-Day Moving Average of the stock is 5.13%, while the 200-Day Moving Average is calculated to be 46.97%.
Shares Statistics:
The stock has traded on average 3.12M shares per day over the past 3-months and 1857100 shares per day over the last 10 days, according to various share statistics. A total of 106.24M shares are outstanding, with a floating share count of 98.88M. Insiders hold about 7.00% of the company’s shares, while institutions hold 82.99% stake in the company. Shares short for ITCI as of 1740700800 were 2334807 with a Short Ratio of 0.75, compared to 1738281600 on 1603446. Therefore, it implies a Short% of Shares Outstanding of 2334807 and a Short% of Float of 2.22.
